The human polyomavirus, JCV, uses serotonin receptors to infect cells

Science

Volumn 306, Issue 5700, 2004, Pages 1380-1383

  Elphick, Gwendolyn F ^a   Querbes, William ^a,b   Jordan, Joslynn A ^a,b   Gee, Gretchen V ^a,b   Eash, Sylvia ^a,b   Manley, Kate ^a,b   Dugan, Aisling ^a,b   Stanifer, Megan ^a,b   Bhatnagar, Anushree ^c   Kroeze, Wesley K ^c   Roth, Bryan L ^c   Atwood, Walter J ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELLS; PATIENT MONITORING; VIRUSES;

CELLULAR RECEPTORS; HUMAN POLYOMAVIRUS; SEROTONERGIC RECEPTORS;

DISEASES;

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; KETANSERIN; METOCLOPRAMIDE; MINAPRINE; MONOCLONAL ANTIBODY; PERGOLIDE; RECEPTOR ANTIBODY; RITANSERIN; SB 20655; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2A RECEPTOR MONOCLONAL ANTIBODY; SEROTONIN 2C RECEPTOR MONOCLONAL ANTIBODY; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

VIRUS;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOSOME; GENETIC TRANSFECTION; GLIA CELL; HELA CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INTERNALIZATION; JC VIRUS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIMIAN VIRUS 40; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; CELL LINE, TRANSFORMED; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENDOSOMES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HELA CELLS; HUMANS; JC VIRUS; MICROSCOPY, CONFOCAL; NEUROGLIA; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE; RECEPTORS, VIRUS; SEROTONIN; SEROTONIN ANTAGONISTS; SIALIC ACIDS; TRANSFECTION;

JC VIRUS; POLYOMAVIRUS; SIMIAE; SIMIAN VIRUS 40;

EID: 8844269161     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1103492     Document Type: Article

References (40)

1. R. C. Holman, T. J. Torok, E. D. Belay, R. S. Janssen, L. B. Schonberger, Neuroepidemiology 17, 303 (1998).
2. D. L. Walker, R. J. Frisque, in The Papovaviridae, N. P. Salzman, ed. (Plenum, New York and London, 1986), pp. 327-377.
3. S. Bofill-Mas, S. Pina, R. Girones, Appl. Environ. Microbiol. 66, 238 (2000).
4. J. R. Berger, E. O. Major, Semin. Neurol. 19, 193 (1999).
5. S. A. Houff et al., N. Engl. J. Med. 318, 301 (1988).
6. M. G. C. Monaco, W. J. Atwood, M. Gravell, C. S. Tornatore, E. O. Major, J. Virol. 70, 7004 (1996).
7. M. C. Monaco, P. N. Jensen, J. Hou, L. C. Durham, E. O. Major, J. Virol. 72, 9918 (1998).
8. C. K. Liu, G. Wei, W. J. Atwood, J. Virol. 72, 4643 (1998).
9. S. Eash et al., Am. J. Pathol. 164, 419 (2004).
10. B. J. Chen, W. J. Atwood, Virology 300, 282 (2002).
11. M. T. Pho, A. Ashok, W. J. Atwood, J. Virol. 74, 2288 (2000).
12. W. Querbes, A. Benmerah, D. Tosoni, P. P. Di Fiore, W. J. Atwood, J. Virol. 78, 250 (2004).
13. L. Pelkmans, J. Kartenbeck, A. Helenius, Nature Cell Biol. 3, 473 (2001).
14. L. C. Norkin, Immunol. Rev. 168, 13 (1999).
15. L. C. Norkin, H. A. Anderson, S. A. Wolfrom, A. Oppenheim, J. Virol. 76, 5156 (2002).
16. S. Baum et al., J. Neurovirol. 9, 32 (2003).
17. A. Newman-Tancredi et al., J. Pharmacol. Exp. Ther. 303, 815 (2002).
18. M. Velasco, A. Luchsinger, Am. J. Ther. 5, 37 (1998).
19. K. Herrick-Davis, E. Grinde, M. Teitler, J. Pharmacol. Exp. Ther. 295, 226 (2000).
20. P. K. Gillman, J. Psychopharmacol. 13, 100 (1999).
21. F. G. Boess, I. L. Martin, Neuropharmacology 33, 275 (1994).
22. M. S. Choudhary, S. Craigo, B. L. Roth, Mol. Pharmacol. 42, 627 (1992).
23. M. Dudley, A. Ogden, A. Carr, T. Nieduzak, J. Kehne, Soc. Neurosci. Abstr. 16, 1037 (1990).
24. J. L. Herndon, A. Ismaiel, S. P. Ingher, M. Teitler, R. A. Glennon, J. Med. Chem. 35, 4903 (1992).
25. K. Kristiansen, S. G. Dahl, Eur. J. Pharmacol. 306, 195 (1996).
26. A. Bhatnagar et al., J. Biol. Chem. 276, 8269 (2001).
27. D. Hoyer et al., Pharmacol. Rev. 46, 157 (1994).
28. A. Bhatnagar, D. J. Sheffler, W. K. Kroeze, B. Compton-Toth, B. L. Roth, J. Biol. Chem. 279, 34614 (2004).
29. C. Mandl, D. L. Walker, R. J. Frisque, J. Virol. 61, 755 (1987).
30. B. Padgett, G. ZuRhein, D. Walker, R. Echroade, B. Dessel, Lancet I, 1257 (1971).
31. E. O. Major et al., Proc. Natl. Acad. Sci. U.S.A. 82, 1257 (1985).
32. G. Wei, C. K. Liu, W. J. Atwood, J. Neurovirol. 6, 127 (2000).
33. A. Merzak, S. Koochekpour, M. P. Fillion, G. Fillion, G. J. Pilkington, Brain Res. Mol. Brain Res. 41, 1 (1996).
34. Z. Cohen et al., J. Cereb. Blood Flow Metab. 19, 908 (1999).
35. M. I. Fonseca, Y. G. Ni, D. D. Dunning, R. Miledi, Brain Res. Mol. Brain Res. 89, 11 (2001).
36. S. Belachew et al., Neuroreport 9, 973 (1998).
37. J. A. Gray et al., Mol. Pharmacol. 60, 1020 (2001).
38. D. W. Bonhaus et al., Br. J. Pharmacol. 115, 622 (1995).
39. M. Chang, L. Zhang, J. P. Tam, E. Sanders-Bush, J. Biol. Chem. 275, 7021 (2000).
40. We would like to thank all members of the Atwood laboratory for critical discussion during the course of this work. We thank J. Sedivy for critical discussions during the preparation of the manuscript. We also thank L. Brossay for the pMSCV plasmid, R. Creton for critical help with confocal microscopy, and A. Robinson, A. Bozek, and L. St. Pierre for administrative assistance. Work in our laboratory was supported by a grant from the National Cancer Institute, R01 CA71878, and by a grant from the National Institute of Neurological Disorders and Stroke, R01 NS43097. W.Q. is supported by a Graduate Assistantship in Areas of National Need training grant from the Department of Education, P200A030100. Work in the Roth lab was supported by RO1MH57635, RO1MH61887, and the National Institute of Mental Health Psychoactive Drug Screening Program to B.L.R.